These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11331 related articles for article (PubMed ID: 11092052)
1. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. Abken H; Hombach A; Heuser C; Reinhold U Recent Results Cancer Res; 2001; 158():249-64. PubMed ID: 11092052 [TBL] [Abstract][Full Text] [Related]
2. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766 [TBL] [Abstract][Full Text] [Related]
3. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases. Hombach A; Pohl C; Reinhold U; Abken H Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789 [TBL] [Abstract][Full Text] [Related]
5. Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain. Losch FO; Müller R; Mutschler B; Neri D; Natali PG; Reth M; Carsetti R Int J Cancer; 2003 Jan; 103(3):399-407. PubMed ID: 12471624 [TBL] [Abstract][Full Text] [Related]
6. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Kruis W; Pohl C; Abken H Gastroenterology; 1997 Oct; 113(4):1163-70. PubMed ID: 9322511 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745 [TBL] [Abstract][Full Text] [Related]
8. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Hombach A; Schneider C; Sent D; Koch D; Willemsen RA; Diehl V; Kruis W; Bolhuis RL; Pohl C; Abken H Int J Cancer; 2000 Oct; 88(1):115-20. PubMed ID: 10962448 [TBL] [Abstract][Full Text] [Related]
9. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Burns WR; Zhao Y; Frankel TL; Hinrichs CS; Zheng Z; Xu H; Feldman SA; Ferrone S; Rosenberg SA; Morgan RA Cancer Res; 2010 Apr; 70(8):3027-33. PubMed ID: 20395199 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860 [TBL] [Abstract][Full Text] [Related]
11. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477 [TBL] [Abstract][Full Text] [Related]
12. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559 [TBL] [Abstract][Full Text] [Related]
13. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Yun CO; Nolan KF; Beecham EJ; Reisfeld RA; Junghans RP Neoplasia; 2000; 2(5):449-59. PubMed ID: 11191112 [TBL] [Abstract][Full Text] [Related]
14. The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Hombach A; Heuser C; Abken H Curr Gene Ther; 2002 May; 2(2):211-26. PubMed ID: 12109217 [TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains. Hombach A; Sircar R; Heuser C; Tillmann T; Diehl V; Kruis W; Pohl C; Abken H Int J Mol Med; 1998 Jul; 2(1):99-103. PubMed ID: 9854151 [TBL] [Abstract][Full Text] [Related]
16. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. Anikeeva N; Panteleev S; Mazzanti NW; Terai M; Sato T; Sykulev Y J Biol Chem; 2021 Sep; 297(3):101033. PubMed ID: 34371020 [TBL] [Abstract][Full Text] [Related]
17. Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma. Uslu U; Schuler G; Dörrie J; Schaft N Exp Dermatol; 2016 Nov; 25(11):872-879. PubMed ID: 27246630 [TBL] [Abstract][Full Text] [Related]
19. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma. Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060 [TBL] [Abstract][Full Text] [Related]
20. The T-body approach: redirecting T cells with antibody specificity. Eshhar Z Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]